4Filed Sep 8, 8:00 PM ET

Bio‑Rad (BIO) CFO Lakkaraju Exercises RSUs; Shares Withheld for Taxes

$BIO BIO.B · BIO-RAD LABORATORIES, INC.

Research Summary

AI-generated summary of this SEC filing

Updated

Bio‑Rad (BIO) CFO Lakkaraju Exercises RSUs; Shares Withheld for Taxes

What Happened

  • Lakkaraju Roop Kalyan, Chief Financial Officer of Bio‑Rad Laboratories (BIO), had restricted stock units (RSUs) involved in a multi‑day vest/conversion. A grant of 6,326 RSUs was recorded on 2026‑09‑04. On 2026‑09‑05 he converted 1,370 RSUs into shares and on 2026‑09‑06 converted 1,536 RSUs into shares (total converted = 2,906 shares). To cover tax withholding, the company withheld/disposed 559 shares on 09/05 (valued at $386.11 each = $215,835) and 782 shares on 09/06 (valued at $386.11 each = $301,938), totaling 1,341 shares withheld and ~$517,773 in cash. These entries reflect RSU vesting and share withholding for taxes rather than an open‑market sale.

Key Details

  • Transaction dates/prices:
    • 2026‑09‑04: Grant of 6,326 RSUs (derivative award, $0 exercise price).
    • 2026‑09‑05: Conversion of 1,370 RSUs to shares (M); 559 shares withheld at $386.11 for taxes ($215,835).
    • 2026‑09‑06: Conversion of 1,536 RSUs to shares (M); 782 shares withheld at $386.11 for taxes ($301,938).
  • Total withheld for taxes: 1,341 shares → ~$517,773.
  • Footnotes: Each RSU equals one contingent share; RSUs vest over four years (25% first anniversary, remainder in equal quarterly installments). Filing notes include 22.0680 shares acquired under the ESPP on 06/30/2026.
  • Shares owned after these transactions are not provided in the supplied excerpt.
  • Filing: Form 4 filed 2026‑09‑09 while transactions occurred 2026‑09‑04 to 09‑06; this is several days after the transactions and may be later than the standard two business‑day Form 4 deadline.

Context

  • Codes: A = grant/award (RSUs); M = exercise/conversion of a derivative (RSU conversion to common shares); F = payment of exercise price or tax liability (share withholding to cover taxes). The withholding here is a routine tax withholding mechanism (not an open‑market sale).
  • For retail investors: this filing shows executive compensation being realized (vesting/conversion) and routine tax withholding — it does not represent a discretionary cash sale into the market that would more strongly signal insider sentiment.